Chemoprevention: Mouse colon and lung tumor bioassay and modulation of DNA methylation as a biomarker

Experimental Lung Research

Volumn 31, Issue 2, 2005, Pages 145-163

  Pereira, Michael A ^a,c   Tao, Lian H ^a   Wang, Wei ^a   Gunning, William T ^a   Lubet, Ronald ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoprevention; Colon tumors; Dexamethasone; DNA methylation; IGF II; Lung tumors; Piroxicam

Indexed keywords

AZOXYMETHANE; BIOLOGICAL MARKER; BUDESONIDE; CARBAMIC ACID DERIVATIVE; DEXAMETHASONE; DNA; PIROXICAM; SOMATOMEDIN B;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BIOASSAY; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON TUMOR; CONFERENCE PAPER; CONTROLLED STUDY; DNA METHYLATION; DOSE RESPONSE; EXON; EXPERIMENTAL NEOPLASM; FEMALE; LONG TERM CARE; LUNG TUMOR; METASTASIS INHIBITION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 14644438586     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/01902140490495534     Document Type: Conference Paper

References (54)

1. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA: Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000;60:1864-1870.
2. Ritland SR, Gendler SJ: Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis. 1999;20:51-58.
3. Li H, Kramer PM, Lubet RA, Steele VE, Kelloff GJ, Pereira MA: Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. Cancer Lett. 1999;147:187-193.
4. Pereira MA, Barnes LH, Steele VE, Kelloff GV, Lubet RA: Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis. 1996;17:373-376.
5. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS: Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16-alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 1991;51:4528-4534.
6. Reddy BS, Maruyama H, Kelloff G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 1987;47:5340-5346.
7. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha- difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 1990;50:2562-2568.
8. Witschi H, Espiritu I, Uyeminami D: Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. Carcinogenesis. 1999;20:1375-1378.
9. Wattenberg LW, Estensen RD: Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-(methylnitrosoamino)-1-(3-pyridyl)-1- butanone-induced pulmonary carcinogenesis in female A/J mice. Cancer Res. 1996;56:5132-5135.
10. Moen CJ, van der Valk MA, Bird RP, Hart AA, Demant P: Different genetic susceptibility to aberrant crypts and colon adenomas in mice. Cancer Res. 1996;56:2382-2386.
11. Papanikolaou A, Wang QS, Delker DA, Rosenberg DW: Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett. 1998;130:29-34.
12. Turusov VS, Lanko NS, Krutovskikh VA, Parfenov YD: Strain differences in susceptibility of female mice to 1,2-dimethylhydrazine. Carcinogenesis. 1982;3:603-608.
13. Stoner GD, Conran PB, Greisiger EA, Stober J, Morgan M, Pereira MA: Comparison of two routes of chemical administration on the lung adenoma response in strain A/J mice. Toxicol Appl Pharmacol. 1986;82:19-31.
14. Stoner GD, Greisiger EA, Schut HA, Pereira MA, Loeb TR, Klaunig JE, Branstetter DG: A comparison of the lung adenoma response in strain A/J mice after intraperitoneal and oral administration of carcinogens. Toxicol Appl Pharmacol. 1984;72:313-323.
15. Bolt AB, Papanikolaou A, Delker DA, Wang QS, Rosenberg DW: Azoxymethane induces Ki-ras activation in the tumor resistant AKR/J mouse colon. Mol Carcinog. 2000;27:210-218.
16. Allen JW, Stoner GD, Pereira MA, Backer LC, Sharief Y, Hatch GG, Campbell JA, Stead AG, Nesnow S: Tumorigenesis and genotoxicity of ethyl carbamate and vinyl carbamate in rodent cells. Cancer Res. 1986;46:4911-4915.
17. Dahl GA, Miller JA, Miller EC: Vinyl carbamate as a promutagen and a more carcinogenic analog of ethyl carbamate. Cancer Res. 1978;38:3793-3804.
18. Donnelly PJ, Devereux TR, Foley JF, Maronpot RR, Anderson MW, Massey TE: Activation of K-ras in aflatoxin B1-induced lung tumors from AC3F1 (A/J x C3H/HeJ) mice. Carcinogenesis. 1996;17:1735-1740.
19. Wang Y, Stoner G, You M: ras mutations in 2-acetylaminofluorene-induced lung and liver tumors from C3H/HeJ and (C3H x A/J) F1 mice. Cancer Res. 1993;53:1620-1624.
20. You M, Wang Y, Stoner G, You L, Maronpot R, Reynolds SH, Anderson M: Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids. Proc Natl Acad Sci U S A. 1992;89:5804-5808.
21. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
22. Bird A: The relationship of DNA methylation to cancer. Cancer Surveys. 1996;28:87-101.
23. Counts JL, Goodman JI: Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion. Progr Clin Biol Res. 1995;391:81-101.
24. Tao L, Kramer PM, Ge R, Pereira MA: Effect of dichloroacetic acid and trichloroacetic acid on DNA methylation in liver and tumors of female B6C3F1 mice. Toxicol Sci. 1998;43:139-144.
25. Tao L, Wang W, Kramer PM, Lubet RA, Steele VE, Pereira MA: Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Mol Carcinog. 2004;39: 79-84.
26. Tao L, Li Y, Wang W, Kramer PM, Gunning W T, Lubet RA, Steele VE, Pereira MA: Effect of budesonide on the methylation and mRNA expression of the insulin-like growth factor 2 and c-myc genes in mouse lung tumors. Mol Carcinog. 2002;35:93-102.
27. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472-1489.
28. O'Dell SD, Day IN: Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol. 1998;30:767-771.
29. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21:215-244.
30. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 1998;4:1276-1280.
31. Kohda M, Hoshiya H, Katoh M, Tanaka I, Masuda R, Takemura T, Fujiwara M, Oshimura M: Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol Carcinog. 2001;31:184-191.
32. Weber M, Milligan L, Delalbre A, Antoine E, Brunel C, Cathala G, Forne T: Extensive tissue-specific variation of allelic methylation in the Igf2 gene during mouse fetal development: relation to expression and imprinting. Mech Dev. 2001;101:133-141.
33. Brandeis M, Kafri T, Ariel M, Chaillet JR, McCarrey J, Razin A, Cedar,H: The ontogeny of allele-specific methylation associated with imprinted genes in the mouse. EMBO J. 1993;12:3669-3677.
34. Feil R, Walter J, Allen ND, Reik W: Developmental control of allelic methylation in the imprinted mouse Igf2 and H19 genes. Development. 1994;120:2933-2943.
35. Moore T, Constancia M, Zubair M, Bailleul B, Feil R, Sasaki H, Reik W: Multiple imprinted sense and antisense transcripts, differential methylation and tandem repeats in a putative imprinting control region upstream of mouse Igf2. Proc Natl Acad Sci U S A. 1997;94:12509-12514.
36. Hu JF, Nguyen PH, Pham NV, Vu TH, Hoffman AR: Modulation of Igf2 genomic imprinting in mice induced by 5-azacytidine, an inhibitor of DNA methylation. Mol Endocrinol. 1997;11:1891-1898.
37. Pereira MA, Li Y, Gunning WT, Kramer PM, Al-yaqoub, Lubet RA, Steele VE, Szabo E, Tao L: Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcinogenesis, 2002;23:1185-1192.
38. Wattenberg LW, Estensen RD: Studies of chemopreventive effects of budenoside on benzo[a]pyrene-induced neoplasia of the lung of female A/J mice. Carcinogenesis. 1997;18:2015-2017.
39. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ: Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 1997;57:5489-5492.
40. Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DL, Pereira MA, Crowell JA, Bagheri D: Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl. 1994;20:32-54.
41. Olek A, Oswald J, Walter J: A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 1996;24:5064-5066.
42. Kimura I: Progression of pulmonary tumors in mice. 1. Histological studies of primary and transplanted pulmonary tumors. Acta Pathol Jpn. 1971;21:13-56.
43. Kauffman SL, Alexander L, Sass L: Histologic and ultrastructural features of the clara cell adenoma of the mouse lung. Lab Invest. 1979;40:708-716.
44. Kauffman SL: Histogenesis of the papillary Clara cell adenoma. Am J Pathol. 1981;103:174-180.
45. Gunning WT, Kramer PM, Lubet RA, Steele VE, Pereira MA: Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice. Exp Lung Res. 2000;26:757-772.
46. Boone, CW, Steele VE, Kelloff GJ: Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res. 1992;267:251-255.
47. Chen B, Johanson L, Wiest JS, Anderson MW, You M: The second intron of the K-ras gene contains regulatory elements associated with mouse lung tumor susceptibility. Proc Natl Acad Sci U S A. 1994;91:1589-1593.
48. Herzog CR, Lubet RA, You M: Genetic alterations in mouse lung tumors: implications for cancer chemoprevention. J Cell Biochem Suppl. 1997;28-29:49-63.
49. Lin L, Festing MF, Devereux TR, Crist KA, Christiansen SC, Wang Y, Yang A, Svenson K, Paigen B, Malkinson AM, You M: Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res. 1998;24:481-497.
50. Foley JF, Anderson MW, Stoner GD, Gaul BW, Hardisty JF, Maronpot RR: Proliferative lesions of the mouse lung: progression studies in strain A mice. Exp Lung Res. 1991;17:157-168.
51. 3H] dexamethasone binding in urethan-induced mouse lung tumors. Cancer Res. 1984;44:3546-3553.
52. Choudhury C, Kauffman SL, Seravalli E, Durkin H: Lymphocytic infiltration of bronchioloalveolar adenomas in mice. Cancer Lett. 1983;20:299-304.
53. Piyathilake CJ, Johanning GL, Frost AR, Whiteside MA, Manne U, Grizzle WE, Heimburger DC, Niveleau A: Immunohistochemical evaluation of global DNA methylation: comparison with in vitro radiolabeled methyl incorporation assay. Biotech Histochem 2000;75:251-258.
54. Tao L, Wang W, Kramer PM, Lubet RA, Steele VE, Pereira MA: Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Mol Carcinogen. 2004;39:79-84.